Kiniksa Pharmaceuticals International, plc (KNSA) FY2026 YTD Q3 Statement of Cash Flows

Published Source: Form 10-Q on SEC EDGAR filed (opens in a new tab)

2026-01-01 to 2026-09-30

Statement of Cash Flows

Swipe to see the full flow
Kiniksa Pharmaceuticals International, plc cash flow reconciliation, Jan 1, 2026 through Sep 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Net income → Net cash from operating activities: $95,369,000.00Accrued expenses, accrued collaboration expenses and other current liabilities → Operating adjustments reconciliation: $49,690,000.00Share-based compensation expense → Operating adjustments reconciliation: $34,757,000.00Other long-term liabilities → Operating adjustments reconciliation: $26,857,000.00Non-cash lease expense → Operating adjustments reconciliation: $3,010,000.00Accounts payable → Operating adjustments reconciliation: $2,081,000.00Depreciation and amortization expense → Operating adjustments reconciliation: $1,430,000.00Net amortization of premiums and accretion of discounts on short-term investments → Operating adjustments reconciliation: $1,053,000.00Deferred income taxes → Operating adjustments reconciliation: $619,000.00Other long-term assets → Operating adjustments reconciliation: $394,000.00Prepaid expenses and other current assets → Operating adjustments reconciliation: $228,000.00Operating adjustments reconciliation → Net cash from operating activities: $49,572,000.00Operating adjustments reconciliation → Inventory: $53,133,000.00Operating adjustments reconciliation → Accounts receivable, net: $15,185,000.00Operating adjustments reconciliation → Operating lease liabilities: $2,205,000.00Operating adjustments reconciliation → Net gain on disposal of property and equipment: $24,000.00Proceeds from issuance of Class A ordinary shares under incentive award plans and employee share purchase plan → financing reconciliation: $30,042,000.00financing reconciliation → Net cash from financing activities: $15,183,000.00financing reconciliation → Payments in connection with ordinary shares tendered for employee tax obligations: $14,859,000.00Net cash used in investing activities → investing reconciliation: $244,060,000.00Proceeds from the maturities of short-term investments → investing reconciliation: $214,100,000.00investing reconciliation → Purchases of short-term investments: $457,156,000.00investing reconciliation → Purchases of property and equipment: $1,004,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $165,596,000.00Net cash from operating activities → Cash sources and uses: $144,941,000.00Net cash from financing activities → Cash sources and uses: $15,183,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $81,660,000.00Cash sources and uses → Net cash used in investing activities: $244,060,000.00Net income: $95,369,000.00Net income+$95.37 MDepreciation and amortization expense: $1,430,000.00Depreciation & amortization+$1.43 MShare-based compensation expense: $34,757,000.00Stock-based compensation+$34.76 MNet gain on disposal of property and equipment: -$24,000.00PP&E disposal gain & loss−$24.00 KNon-cash lease expense: $3,010,000.00Non-cash lease expense+$3.01 MNet amortization of premiums and accretion of discounts on short-term investments: $1,053,000.00Investment discount & premium+$1.05 MDeferred income taxes: $619,000.00Deferred income taxes+$619.00 KPrepaid expenses and other current assets: $228,000.00Prepaid & other assets+$228.00 KAccounts receivable, net: -$15,185,000.00Accounts receivable−$15.19 MInventory: -$53,133,000.00Inventories−$53.13 MOther long-term assets: $394,000.00Other noncurrent assets+$394.00 KAccounts payable: $2,081,000.00Accounts payable+$2.08 MAccrued expenses, accrued collaboration expenses and other current liabilities: $49,690,000.00Accrued liabilities+$49.69 MOperating lease liabilities: -$2,205,000.00Operating lease liabilities−$2.21 MOther long-term liabilities: $26,857,000.00Other noncurrent liabilities+$26.86 MNet cash from operating activities: $144,941,000.00Operating cash+$144.94 MOperating adjustments reconciliation: $120,119,000.00Proceeds from issuance of Class A ordinary shares under incentive award plans and employee share purchase plan: $30,042,000.00Employee stock plan proceeds+$30.04 MPayments in connection with ordinary shares tendered for employee tax obligations: -$14,859,000.00Stock-award tax withholding−$14.86 MNet cash from financing activities: $15,183,000.00Financing cash+$15.18 Mfinancing reconciliation: $30,042,000.00Purchases of property and equipment: -$1,004,000.00PP&E purchases−$1.00 MPurchases of short-term investments: -$457,156,000.00Short-term investment purchases−$457.16 MProceeds from the maturities of short-term investments: $214,100,000.00Short-term investment maturities+$214.10 MNet cash used in investing activities: -$244,060,000.00. Cash required to fund net payments.Investing cash−$244.06 Minvesting reconciliation: $458,160,000.00Cash sources and uses: $325,720,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $165,596,000.00Beginning cash$165.60 MEnding cash: Cash, cash equivalents, and restricted cash: $81,660,000.00Ending cash$81.66 MCASH RECONCILIATIONOperatingflowsFinancingflowsInvestingflowsFree cash flow$143.94 MOperating cash − cash spent on PP&ECash flow / Net income1.52×Operating cash flow ÷ net incomeNet cash change−$83.94 MEnding cash − beginning cash
Chart details

Kiniksa Pharmaceuticals International, plc cash flow reconciliation, Jan 1, 2026 through Sep 30, 2026

Cash flows for Jan 1, 2026 through Sep 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2025. Ending cash: Sep 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2025
165,596,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
144,941,000 US dollars. Net cash provided.
Net income
95,369,000 US dollars
Depreciation and amortization expense
1,430,000 US dollars
Share-based compensation expense
34,757,000 US dollars
Net gain on disposal of property and equipment
negative 24,000 US dollars
Non-cash lease expense
3,010,000 US dollars
Net amortization of premiums and accretion of discounts on short-term investments
1,053,000 US dollars
Deferred income taxes
619,000 US dollars
Prepaid expenses and other current assets
228,000 US dollars
Accounts receivable, net
negative 15,185,000 US dollars
Inventory
negative 53,133,000 US dollars
Other long-term assets
394,000 US dollars
Accounts payable
2,081,000 US dollars
Accrued expenses, accrued collaboration expenses and other current liabilities
49,690,000 US dollars
Operating lease liabilities
negative 2,205,000 US dollars
Other long-term liabilities
26,857,000 US dollars
Investing activities
negative 244,060,000 US dollars. Net cash used.
Purchases of property and equipment
negative 1,004,000 US dollars
Purchases of short-term investments
negative 457,156,000 US dollars
Proceeds from the maturities of short-term investments
214,100,000 US dollars
Financing activities
15,183,000 US dollars. Net cash provided.
Proceeds from issuance of Class A ordinary shares under incentive award plans and employee share purchase plan
30,042,000 US dollars
Payments in connection with ordinary shares tendered for employee tax obligations
negative 14,859,000 US dollars
Operating adjustment reconciliation
120,119,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
30,042,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
458,160,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
0 US dollars
Ending cash on Sep 30, 2026
81,660,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
325,720,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
negative 83,936,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
1.52×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
Operating cash flow
144,941,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
1,004,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
143,937,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net income enters operating cash directly in the reconciliation. The adjustment junction contributes the remaining $49.57M after reconciling the other positive and negative adjustments. These connections depict an accounting reconciliation, not traced cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 144,941,000 US dollars minus 1,004,000 US dollars equals 143,937,000 US dollars.
Kiniksa Pharmaceuticals International, plc (KNSA) FY2026 YTD Q3 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!